AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
AstraZeneca PLC is keeping a tight lid on Phase III data for its biologic for severe asthma, benralizumab, other than to say it met its primary endpoint in a pair of pivotal trials – but the pharma hopes to offer differentiating efficacy from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. biologics already approved for this indication when it unveils the full datasets at a scientific meeting later this year.
You may also be interested in...
From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.
AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.
Teva Pharmaceutical Industries Ltd. gained US approval on March 23 to market Cinqair (reslizumab) as an add-on maintenance treatment for adults 18 years or older with severe asthma with an eosinophilic phenotype.